DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lipoid proteinosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLipoid proteinosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lipoid proteinosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Lipoid proteinosis is an autosomal recessive disorder caused by loss-of-function mutations in the extracellular matrix protein 1 gene (ECM1) on chromosome 1q21.1, leading to reduced or absent expression of that protein. The condition involves multisystem intracellular deposition of noncollagenous proteins and glycoproteins, and histologically shows widespread hyaline material deposition with disruption or reduplication of basement membrane. A 1972 case report described an extracellular, finely granular, amorphous material in patchy distribution throughout the dermis and around blood vessels in the eyelids and lip, with normal collagen fibres; the authors suggested that differences from earlier reports might reflect biopsy at different stages of lesion development.
Clinically, the disorder is characterised by skin scarring and infiltration, vocal cord thickening causing hoarseness, and diffuse skin thickening that can affect the tongue, with pitted scarring on the face and upper trunk. A 2003 report followed a 14-year-old Pakistani boy with consanguineous parents who had progressive hoarseness since early infancy and relatively mild skin signs. Molecular analysis identified a homozygous C-to-T transition at nucleotide 1036 in exon 7 of ECM1, designated Q346X, predicted to cause loss of function of the ECM1a isoform. Ten different homozygous mutations had been identified across patients from several countries, all nonsense, frameshift, or internal deletion mutations leading to loss of ECM1 function.
No treatment or intervention is discussed in any of these abstracts. No data on survival, response rates, or sample sizes beyond single cases are provided. The natural history and clinical variability are described, but no controlled studies or therapeutic trials exist in this material.
What remains missing is any funded clinical trial, any systematic attempt to stratify patients by mutation type or disease severity, and any evidence that a specific drug can modify the deposition process or clinical course.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Ophthalmology · 1972 · 18 citations
Lipoid Proteinosis
AbstractThe clinical and histopathologic findings in a case of lipoid proteinosis are described. Electron micrographs demonstrated the presence of an extracellular, finely granular, amorphous material located in patchy distribution throughout the dermis and about blood vessels in the lids and lip. Collagen fibers were normal. It is suggested that the different character of these deposits as compared to those in previous reports might be the result of the biopsy of lesions at different stages of development.
Archives of Dermatology and Syphilology · 1947 · 18 citations
LIPOIDOSIS CUTIS ET MUCOSAE
AbstractLIPOIDOSIS cutis et mucosae has been reported so infrequently as to be considered a rare disease. However, sufficient cases 1 have been presented in the literature so that it emerges as a well defined clinical entity with a pathognomonic histopathologic picture. According to Urbach, 2 the disease is characterized by abnormal deposits of lipids in the skin, mucous membranes and possibly also in other tissues. From histochemical studies employing differential staining procedures and solubilities in various organic solvents, Urbach came to the conclusion that the lipid was of the group of acetone-soluble phosphatides and that it was combined with protein in a physical adsorptive union. Therefore, he suggested the name lipoid proteinosis for this disease. 3 In support of this concept, Montgomery and Havens 4 and J. Ramos e Silva 5 were able to show a decided increase in the phospholipid content of lesions which were subjected to chemical analysis.
American Journal of Dermatopathology · 1988 · 13 citations
A Clinicopathologic Study of Six Cases of Lipoid Proteinosis
AbstractWe have reviewed the clinical and histological presentations of six cases of lipoid proteinosis. Deposits in the dermis were heterogeneous in nature and location. In the first stage of the disease's evolution, basement membrane components accumulate at the normal site of vascular, muscular, and epithelial basement membranes. Later on, lipids and amorphous material fill the superficial dermis, pushing apart the normal collagen bundles. Such deposits seem to be organized around preserved reticulin fibers. The amorphous material did not react with antibodies to collagen types I, III, IV, and V.
AbstractLipoid proteinosis (LiP) results from a multisystem intracellular deposition of noncollagenous proteins and glycoproteins. This deposition appears to be related to the synthesis and metabolism of collagen and is a result of an autosomal recessive mutation with loss-of-function and reduced or absent expression of the extracellular matrix protein 1 gene ( ECM1 ) on chromosome 1q21.1
British Journal of Dermatology · 2003 · 1 citations
A case of lipoid proteinosis with molecular diagnosis
AbstractLipoid proteinosis (OMIM 247100) is a rare, autosomal recessive disorder characterized by skin scarring and infiltration as well as vocal cord thickening leading to hoarseness. Histologically, there is widespread deposition of hyaline material and disruption/reduplication of basement membrane. Recently, we have mapped the disorder to 1q21 and identified the gene for lipoid proteinosis as the extracellular matrix protein 1 gene, ECM11 Ten different homozygous mutations have now been identified in patients from a number of different countries. In each case, the sequence changes comprise nonsense, frameshift, or internal deletion mutations leading to loss‐of‐function of ECM11. We report here the case of a 14‐year‐old Pakistani boy with consanguinous parents, whom we have followed at St Thomas’ Hospital since early childhood. He has had progressive hoarseness since early infancy. Skin signs are relatively mild. There is diffuse skin thickening, which also affects the tongue, and pitted scarring on the face and upper trunk. Molecular analysis revealed a homozygous C>T transition at nucleotide 1036 in exon 7 of ECM1 ; the mutation is designated Q346X, which is predicted to result in loss of function of the ECM1a isoform.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
